Intas to Build a Large-Scale MAb Manufacturing Unit in India
Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).
Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).
The facility, dedicated for MAbs, will undertake large-scale manufacturing of the recombinant product with a capacity of 5,000 L in phases. The government of Gujarat will help the company obtain incentives under various schemes announced by the state and central government.
IBPL is already manufacturing and marketing biosimilars including GCSF, Interferon, Erythropoietin, and PEG-GCSF. The commercial production at the proposed MAbs facility is likely to commence by 2011.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
